US Edition
Women's Health Expert Dr. Larkin Addresses Hormone Therapy ...
SPOKANE COUNTY, WASHINGTON, JUL 17 – The FDA will review hormone therapy risks after a study linked estrogen-progestin and estrogen-only therapies to specific breast cancer subtypes in over 42,000 women.
- In JAMA Network Open, researchers found clear differences in associations between current estrogen-progestin therapy use and luminal-like breast cancer subtypes, underscoring etiologic heterogeneity.
- After widespread use, hormone replacement therapy has helped alleviate symptoms like hot flashes and poor sleep quality, but use has plummeted in recent years amid concerns over rare side effects.
- The study found OR, 2.51 for luminal A-like and 1.95 for luminal B/ERBB2-like subtypes in healthy-weight women using EPT, with inverse ET association in obese women .
- Food and Drug Administration chief Marty Makary stated `prescriptions for hormone replacement therapy plummeted in the United States, women flushed their pills down the toilet,` and blamed the decline on the halted Women’s Health Initiative trial.
- The authors wrote that future studies on contemporary formulations, patterns of use, and routes of administration are warranted.
75 Articles
75 Articles
MedPage Today
Anti-Aging, Acupuncture and Health NewsRemove Boxed Warning on Hormone Therapy for Menopause, FDA Panel Says
(MedPage Today) -- A panel selected by FDA Commissioner Marty Makary, MD, MPH, unanimously urged the agency to remove the boxed warning on hormone treatments for menopause, arguing that the strong warning has likely discouraged countless women...
Menopause Finally Gets a Seat at the Table
On Thursday, July 17, the FDA held a two-hour briefing featuring political leadership and a panel of doctors to focus on menopausal hormone treatments. Among the issues addressed was a decades-old labeling requirement for estrogen products—a.k.a. the “black box warning.” FDA Commissioner Martin Makary appears willing to consider scrapping it on packaging for localized vaginal estrogen treatment. The FDA should do so: The label is inaccurate and …
Testosterone gel: what happens if it rubs off on other people
Marc Bruxelle/Shutterstock.comA case that first appeared in a medical journal several years ago has recently resurfaced in the media, highlighting an unexpected risk of hormone therapies: a baby girl in Sweden developed unusually large genitals after lying on her father’s bare chest, accidentally exposed to his testosterone gel. The incident is a reminder that hormone treatments, while safe when used correctly, can pose risks to others if proper…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
